Glioblastoma
October 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Glioblastoma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Glioblastoma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Glioblastoma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Glioblastoma every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma.
Authors:Bell JC, Ilkow CS
Institution:Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada. Electronic address: jbell@ohri.ca.
Journal:Cancer Cell. 2017 Aug 14;32(2):133-134. doi: 10.1016/j.ccell.2017.07.012.

2:Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
Authors:Okuda T, Tasaki T, Nakata S, Yamashita K, Yoshioka H, Izumoto S, Kato A, Fujita M
Institution:Department of Neurosurgery, Faculty of Medicine, Kindai University, Osaka, Japan okuda@med.kindai.ac.jp mfujita47@gmail.com. Graduate School of Medicine, Kobe, Japan. okuda@med.kindai.ac.jp mfujita47@gmail.com.
Journal:Anticancer Res. 2017 Jul;37(7):3871-3876.

3:Targeting EGFRvIII for glioblastoma multiforme.
Authors:Yang J, Yan J, Liu B
Institution:The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing 210008, China. Electronic address: baoruiliu@nju.edu.cn.
Journal:Cancer Lett. 2017 Sep 10;403:224-230. doi: 10.1016/j.canlet.2017.06.024. Epub 2017 Jun 23.

4:Adult Glioblastoma.
Authors:Alexander BM, Cloughesy TF
Institution:Brian M. Alexander, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; and Timothy F. Cloughesy, University of California Los Angeles, Los Angeles, CA.
Journal:J Clin Oncol. 2017 Jul 20;35(21):2402-2409. doi: 10.1200/JCO.2017.73.0119. Epub 2017 Jun 22.

5:Survival Outcomes With Short-Course Radiation Therapy in Elderly Patients With Glioblastoma: Data From a Randomized Phase 3 Trial.
Authors:Guedes de Castro D, Matiello J, Roa W, Ghosh S, Kepka L, Kumar N, Sinaika V, Lomidze D, Hentati D, Rosenblatt E, Fidarova E
Institution:AC Camargo Cancer Center, Sao Paulo, Brazil. Electronic address: dougguedes@uol.com.br. Canada. Canada.
Journal:Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):931-938. doi: 10.1016/j.ijrobp.2017.03.037. Epub 2017 Mar 30.

6:Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Authors:Pollom EL, Fujimoto D, Wynne J, Seiger K, Modlin LA, Jacobs LR, Azoulay M, von Eyben R, Tupper L, Gibbs IC, Hancock SL, Li G, Chang SD, Adler JR, Harsh GR, Harraher C, Nagpal S, Thomas RP, Recht LD, Choi CYH, Soltys SG
Institution:Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California. Electronic address: sgsoltys@stanford.edu.; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California; Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada.; Department of Neurosurgery, Stanford University School of Medicine, Stanford, California.; Department of Neurosurgery, Stanford University School of Medicine, Stanford, California; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California; Department of Radiation Oncology, Santa Clara Valley Medical Center, San Jose, California.
Journal:Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):123-130. doi: 10.1016/j.ijrobp.2017.01.242. Epub 2017 Feb 7.

7:A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Authors:Illic R, Somma T, Savic D, Frio F, Milicevic M, Solari D, Nikitovic M, Lavrnic S, Raicevic S, Milosevic S, Cavallo LM, Cappabianca P, Grujicic D
Institution:Clinic of Neurosurgery, Clinical Center of Serbia, Medical Faculty University of Belgrade, Belgrade, Serbia.; Division of Neurosurgery, Department of Neurosciences and Reproductive and Odontostomatological Sciences, Universita degli Studi di Napoli Federico II, Naples, Italy. Electronic address: teresa.somma85@gmail.com.; Institute for Oncology and Radiology of Serbia, Medical Faculty University of Belgrade, Belgrade, Serbia.; Department of Pathological Anatomy, Clinical Center of Serbia, Medical Faculty University of Belgrade, Belgrade, Serbia.; Department of Radiology and Magnetic Resonance, Clinical Center of Serbia, Medical Faculty University of Belgrade, Belgrade, Serbia.
Journal:World Neurosurg. 2017 Aug;104:581-588. doi: 10.1016/j.wneu.2017.05.018. Epub 2017 May 15.

8:Angiogenesis inhibitors in tackling recurrent glioblastoma.
Authors:Hundsberger T, Reardon DA, Wen PY
Institution:a Department of Neurology and Department of Hematology /Oncology , Cantonal hospital , St. Gallen , Switzerland. Cancer Center , Boston , MA , USA. Cancer Center , Boston , MA , USA.
Journal:Expert Rev Anticancer Ther. 2017 Jun;17(6):507-515. doi: 10.1080/14737140.2017.1322903. Epub 2017 May 2.

9:Recurrence Pattern Analysis of Primary Glioblastoma.
Authors:Rapp M, Baernreuther J, Turowski B, Steiger HJ, Sabel M, Kamp MA
Institution:Department of Neurosurgery, Medical Faculty, Heinrich Heine University Dusseldorf, Dusseldorf, Germany. Electronic address: marion.rapp@med.uni-duesseldorf.de.; Institute for Diagnostic and Interventional Radiology, Medical Faculty, Heinrich Heine University Dusseldorf, Dusseldorf, Germany.
Journal:World Neurosurg. 2017 Jul;103:733-740. doi: 10.1016/j.wneu.2017.04.053. Epub 2017 Apr 19.

10:Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.
Authors:Poon CC, Sarkar S, Yong VW, Kelly JJP
Institution:Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. Canada. Canada. Canada.
Journal:Brain. 2017 Jun 1;140(6):1548-1560. doi: 10.1093/brain/aww355.

11:Biomarkers and Immunotherapeutic Targets in Glioblastoma.
Authors:Hung AL, Garzon-Muvdi T, Lim M
Institution:Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Baltimore, Maryland, USA. Baltimore, Maryland, USA. Electronic address: Mlim3@jhmi.edu.
Journal:World Neurosurg. 2017 Jun;102:494-506. doi: 10.1016/j.wneu.2017.03.011. Epub 2017 Mar 12.

12:On glioblastoma and the search for a cure: where do we stand?
Authors:Bianco J, Bastiancich C, Jankovski A, des Rieux A, Preat V, Danhier F
Institution:Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Universite catholique de Louvain, Avenue Mounier 73, bte B1 73.12, 1200, Brussels, Belgium. john.bianco@uclouvain.be. Universite catholique de Louvain, Avenue Mounier 73, bte B1 73.12, 1200, Brussels, Belgium. B1.54.10, 1200, Brussels, Belgium. Belgium. Universite catholique de Louvain, Avenue Mounier 73, bte B1 73.12, 1200, Brussels, Belgium. 1348, Louvain-la-Neuve, Belgium. Universite catholique de Louvain, Avenue Mounier 73, bte B1 73.12, 1200, Brussels, Belgium. veronique.preat@uclouvain.be. Universite catholique de Louvain, Avenue Mounier 73, bte B1 73.12, 1200, Brussels, Belgium.
Journal:Cell Mol Life Sci. 2017 Jul;74(13):2451-2466. doi: 10.1007/s00018-017-2483-3. Epub 2017 Feb 17.

13:Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma.
Authors:Ellsworth S, Ye X, Grossman SA
Institution:Brain Cancer Program, Johns Hopkins University School of Medicine, Baltimore, MD.
Journal:Am J Clin Oncol. 2017 Jun;40(3):219-222. doi: 10.1097/COC.0000000000000136.

For a FREE PREVIEW of the Medifocus Guidebook on Glioblastoma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Glioblastoma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Glioblastoma...
at a Special 20% Discount


Medifocus Guidebook on Glioblastoma

Updated: June 21, 2017
192 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Glioblastoma is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

GL32711063

Coupon Expires: December 20, 2017



What Our Customers Are Saying...

"To be diagnosed with a glioblastoma is devastating news. The MediFocus Guidebook on Glioblastoma clearly explained medical terms and adopted a positive approach although not discounting the problems."
E.S.
London, England


"Your Guidebook was EXTREMELY helpful and full of valuable information. I was able to understand "doctor language" and sound educated myself. It was well worth the price."
D.S.
Fairview, Tennessee


"I had never heard of Glioblastoma until one of my relatives was diagnosed with it and was given a very pessimistic outlook. Your Guidebook provided me with the background and sources of additional information necessary to allow me to be of help to him as he decided on his treatment options."
R.W.R.
Pittsfield, Massachusetts



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.